A Study of TRK-950 in Patients With Advanced Solid Tumors

This study is testing a new drug called TRK-950, which is designed to help the immune system fight cancer, in patients with advanced or metastatic solid tumors. Some parts of the study involve TRK-950 alone, some in combination with an existing immunotherapy (nivolumab), and one part targets advanced melanoma. **You may be eligible if:** - You are at least 18 years old - You have a confirmed advanced or metastatic solid tumor - Your cancer has either not responded to standard treatments or no standard treatment exists - You have a life expectancy of at least 3 months - You are able to give written consent - You have a negative pregnancy test if you could become pregnant **You may NOT be eligible if:** - You have an active, uncontrolled bacterial, viral, or fungal infection - You are pregnant or breastfeeding - You test positive for HIV - You are unwilling or unable to follow the study procedures Talk to your doctor to see if this trial is right for you.